Biggest News Aggregation in the World
📰 Data From News

Data From News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Data From. Real-time updates on events, politics, business and more.

Genmab A/S: Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide
United States Judith Klimovsky Hematol Hemoter Asia Pacific Joshua Brody David Freundel

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of ...
United States Judith Klimovsky Asia Pacific Hematol Hemoter Joshua Brody Lymphoma Research Foundation

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics...
United States Hematol Hemoter Mariana Cota Stirner Us Inc European Union Data From The Observational National Lymphocare Study

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science